حجم سوق العلاج بالأدوية المساعدة (Mat) وتحليل الاتجاهات حتى عام 2029

Global Medication Assisted Treatment Mat Market

حجم السوق بالمليار دولار أمريكي

CAGR : 9.00 %

فترة التنبؤ	2022 –2029
حجم السوق (السنة الأساسية)	USD 8,191.94 Million
حجم السوق (سنة التنبؤ)	USD 16,808.38 Million
CAGR	9.00 %
اللاعبين الرئيسيين في الأسواق	Indivior PLC Orexo US Recovery Centers of America Alkermes Sun Pharmaceutical Industries

>السوق العالمية للعلاج بمساعدة الأدوية (MAT)، حسب النوع (الدواء والعلاج)، المنتجات (بوبرينورفين ونالوكسون، نالتريكسون، بوبرينورفين، الميثادون، نالوكسون، ديسفلفرام وأكامبروسيت)، نوع الدواء (الأدوية الجنيسة والعلامات التجارية)، شكل الجرعة (الإطلاق الفوري والإطلاق الممتد)، طريق الإعطاء (عن طريق الفم والحقن وغيرها)، نوع السكان (البالغين والمراهقين)، المستخدم النهائي (عيادات إعادة التأهيل ومراكز المستشفيات المتخصصة والرعاية المنزلية وغيرها)، قناة التوزيع (صيدلية المستشفى، العطاء المباشر، صيدلية التجزئة، الصيدلة عبر الإنترنت وغيرها)، اتجاهات الصناعة والتوقعات حتى عام 2029

تحليل السوق والرؤى

وافقت إدارة الغذاء والدواء على ثلاثة أدوية للاستخدام السريري وهي البوبرينورفين والميثادون والنالتريكسون. يتم تطبيق العلاج بمساعدة الأدوية (MAT) لعلاج اضطراب تعاطي الكحول وأدوية إدمان المواد الأفيونية وأدوية منع جرعة زائدة من المواد الأفيونية. اضطراب تعاطي الكحول (AUD) هو حالة طبية تتميز بضعف القدرة على التوقف عن تعاطي الكحول على الرغم من العواقب الاجتماعية أو المهنية أو الصحية السلبية. أكامبروسيت وديسفلفرام ونالتريكسون هي الأدوية الأكثر شيوعًا المستخدمة لعلاج اضطراب تعاطي الكحول (AUD). دواء إدمان المواد الأفيونية، يزيد من الإدمان على المواد الأفيونية بين المرضى. يتم استخدام البوبرينورفين والميثادون والنالتريكسون لعلاج اضطرابات تعاطي المواد الأفيونية إلى المواد الأفيونية قصيرة المفعول مثل الهيروين والمورفين والكودايين، وكذلك المواد الأفيونية شبه الاصطناعية مثل الأوكسيكودون والهيدروكودون. هذه الأدوية MAT آمنة لشهور أو سنوات أو حتى مدى الحياة. بالنسبة لأدوية الوقاية من الجرعات الزائدة من المواد الأفيونية، يستخدم عقار النالوكسون لمنع الجرعات الزائدة من المواد الأفيونية عن طريق عكس التأثيرات السامة للجرعة الزائدة. ووفقًا لمنظمة الصحة العالمية (WHO) وإدارة خدمات إساءة استخدام المواد والصحة العقلية (SAMHSA)، فإن عقار النالوكسون هو أحد الأدوية العديدة التي تعتبر ضرورية لنظام رعاية صحية فعال.

يعتبر العلاج العالمي بمساعدة الأدوية داعمًا ويهدف إلى تقليل شدة الأعراض. تحلل شركة Data Bridge Market Research أن سوق العلاج بمساعدة الأدوية (MAT) سينمو بمعدل نمو سنوي مركب بنسبة 9.4٪ خلال الفترة المتوقعة من 2022 إلى 2029.

تقرير القياس	تفاصيل
فترة التنبؤ	2022 إلى 2029
سنة الأساس	2021
سنوات تاريخية	2020 (قابلة للتخصيص حتى 2019 - 2014)
وحدات كمية	الإيرادات بالملايين من الدولارات الأمريكية، التسعير بالدولار الأمريكي
القطاعات المغطاة	حسب النوع (الدواء والعلاج)، المنتجات (بوبرينورفين ونالوكسون، نالتريكسون، بوبرينورفين، الميثادون، نالوكسون، ديسفلفرام وأكامبروسيت)، نوع الدواء (الأدوية الجنيسة والعلامات التجارية)، شكل الجرعة (الإطلاق الفوري والإطلاق الممتد)، طريق الإعطاء (عن طريق الفم والحقن وغيرها)، نوع السكان (البالغين والمراهقين)، المستخدم النهائي (عيادات إعادة التأهيل والمستشفيات والمراكز المتخصصة والرعاية المنزلية وغيرها) قناة التوزيع (صيدلية المستشفى، العطاء المباشر، صيدلية التجزئة، صيدلية الإنترنت وغيرها)
الدول المغطاة	حسب البلد (الولايات المتحدة وكندا والمكسيك وألمانيا وفرنسا والمملكة المتحدة وإيطاليا وإسبانيا وروسيا وتركيا وهولندا وسويسرا والنرويج وبولندا والمجر وليتوانيا والنمسا وأيرلندا وبقية أوروبا والصين واليابان وكوريا الجنوبية والهند وأستراليا وسنغافورة وتايلاند وماليزيا وإندونيسيا والفلبين وفيتنام وبقية دول آسيا والمحيط الهادئ والبرازيل والأرجنتين وبيرو وبقية دول أمريكا الجنوبية وجنوب أفريقيا والمملكة العربية السعودية والإمارات العربية المتحدة ومصر وإسرائيل والكويت وبقية دول الشرق الأوسط وأفريقيا)
الجهات الفاعلة في السوق المشمولة	Indivior PLC، Orexo US Inc (شركة تابعة لشركة Orexo AB)، Recovery Centers of America، Alkermes. Sun Pharmaceutical Industries Ltd.، Purdue Pharma LP، Taj Pharmaceuticals Limited، Lannett، Hikma Pharmaceuticals PLC، Pfizer Inc.، Pinnacle Treatment Center، American Addiction Centers، Adamis Pharmaceuticals Corporation، Glenmark Pharmaceutical Inc. Viatris Inc.، Mallinckrodt، Alvogen، Accord Healthcare، VistaPharm, Inc.، Teva Pharmaceutical Industries Ltd. Dr. Reddy's Laboratories Ltd. Amneal Pharmaceuticals LLC. Titan Pharmaceuticals, Inc. وغيرها.

تعريف السوق

يتضمن العلاج بمساعدة الأدوية (MAT) استخدام الأدوية، جنبًا إلى جنب مع الاستشارة والعلاجات السلوكية، لتوفير نهج كامل للمريض لعلاج اضطرابات تعاطي المواد. يستخدم العلاج بمساعدة الأدوية في المقام الأول لعلاج الإدمان على المواد الأفيونية مثل الهيروين ومسكنات الألم الموصوفة طبيًا. يهدف العلاج بمساعدة الأدوية إلى التعافي المناسب، والذي يشمل تحسين بقاء المريض على قيد الحياة، وزيادة استمرار العلاج، وتقليل الاستجابة غير المشروعة، وزيادة نتائج الحمل بين النساء.

ديناميكيات سوق العلاج بمساعدة الأدوية العالمية

السائقين

ارتفاع حالات اضطراب تعاطي الكحول واضطرابات تعاطي المواد الأفيونية

اضطراب تعاطي الكحول هو حالة طبية تتميز بضعف القدرة على التوقف عن تعاطي الكحول أو السيطرة عليه على الرغم من العواقب الاجتماعية أو المهنية أو الصحية السلبية. ويشمل الحالات التي يشير إليها بعض الأشخاص باسم تعاطي الكحول، والاعتماد على الكحول، وإدمان الكحول.

على سبيل المثال،

في عام 2022، ذكرت بيانات منظمة الصحة العالمية (WHO) في المنطقة الأوروبية أن اضطراب الكحول يتسبب في مليون حالة وفاة سنويًا

العلاج بمساعدة الأدوية (MAT) هو استخدام الأدوية مع الاستشارة والعلاجات السلوكية لتوفير نهج "شامل للمريض" لعلاج اضطرابات تعاطي المواد. الأدوية المستخدمة في العلاج بمساعدة الأدوية معتمدة من قبل إدارة الغذاء والدواء (FDA)، وبرامج العلاج بمساعدة الأدوية مدفوعة سريريًا ومصممة لتلبية احتياجات كل مريض.

استخدام التعويض عن العلاج بمساعدة الأدوية (MAT)

قد يكون التعويض متاحًا للعلاج بمساعدة الأدوية حتى لو لم يكن للدواء حالة صالحة.

على سبيل المثال،

في فبراير 2021، طورت الكلية الأمريكية لأطباء الطوارئ (ACEP) الأسئلة الشائعة والترميز الخاص بالسداد والترميز لأغراض إعلامية حول العلاج بمساعدة الأدوية

في حين أنه إذا لم يكن للدواء وضع مفضل، يجب على الطبيب المعالج الحصول على إذن من خطة استحقاقات الصيدلة الخاصة بالعضو.

سوق العلاج بمساعدة الأدوية

فرص

ارتفاع الإنفاق على الرعاية الصحية

علاوة على ذلك، فإن زيادة أنشطة البحث والتطوير وزيادة الاستثمارات من قبل المنظمات الحكومية والخاصة من شأنها أن تعزز فرصًا جديدة لمعدل نمو السوق.

على سبيل المثال،

في فبراير 2021، وفقًا لمؤشر أسعار الرعاية الصحية (HCPI)، ارتفعت ميزانية الرعاية الصحية الإجمالية في الولايات المتحدة بنسبة 3.4%. وتشير الزيادة في النمو إلى أن إنفاق الحكومة الفيدرالية انخفض بشكل كبير في العام السابق من 287.000 مليون دولار أمريكي في عام 2020 إلى 170.000 مليون دولار أمريكي في عام 2021

المبادرة الاستراتيجية من قبل اللاعبين في السوق

لقد زاد الطلب على العلاج بمساعدة الأدوية في الولايات المتحدة وأوروبا بسبب العلاج في الوقت المناسب للحالات المزمنة. تعمل هذه العوامل المواتية على تعزيز الحاجة إلى الأدوية، ولتحقيق الطلب في السوق، يستخدم اللاعبون الصغار والكبار في السوق استراتيجيات مختلفة.

على سبيل المثال،

في أبريل 2021، أعلنت شركة Adamis Pharmaceuticals Corporation بالتعاون مع USWM عن إطلاق وتوافر منتج ZIMHI عالي الجرعة القابل للحقن من عقار النالوكسون للمساعدة في مكافحة الوفيات الناجمة عن جرعات زائدة من المواد الأفيونية. ومن المتوقع أن يؤدي الإطلاق إلى زيادة إيرادات قطاع المنتجات، مما سيعزز نمو السوق، وتوفير ZIMHI بسعر مخفض للمستجيبين الأوائل ومنظمات الصحة المجتمعية

تساعد هذه المبادرات الاستراتيجية التي يتخذها اللاعبون في السوق، بما في ذلك عمليات الاستحواذ والمؤتمرات وإطلاق المنتجات في قطاعات محددة، الشركات على النمو وتحسين محافظ منتجاتها، مما يؤدي في النهاية إلى زيادة توليد الإيرادات. وبالتالي، توفر هذه المبادرات الاستراتيجية التي يتخذها اللاعبون في السوق فرصة تساعدهم على دفع نمو السوق.

القيود/التحديات

الآثار الجانبية للأدوية المستخدمة في العلاج بمساعدة الأدوية (MAT)

يتضمن العلاج بمساعدة الأدوية (MAT) استخدام الأدوية جنبًا إلى جنب مع الاستشارة والعلاجات السلوكية لتوفير نهج "المريض بالكامل" كجزء من استراتيجية العلاج الشاملة. وقد ثبت أن العلاج بمساعدة الأدوية هو الأكثر فعالية في علاج اضطرابات تعاطي الكحول والأفيون. ومع ذلك، تم الإبلاغ عن بعض الآثار الجانبية

على سبيل المثال،

الميثادون والبوبرينورفين، الأدوية العامة، تشبه كيميائيًا المواد الأفيونية، لذا فإن آثارها الجانبية قد تكون متشابهة أيضًا. قد تشمل هذه الآثار الإمساك والنعاس والدوار. قد يعاني بعض الأشخاص من آثار جانبية أكثر شدة

ومن ثم، فمن المتوقع أن تظهر التكلفة المرتفعة الحالية اتجاها تنازليا.

الافتقار إلى المتخصصين المهرة المطلوبين للعلاج بمساعدة الأدوية

إن الافتقار إلى الخبرة الماهرة أو نقصها من شأنه أن يعرقل وتيرة التعافي والنمو في مكان واحد. وكثيراً ما يتمتع العاطلون عن العمل في مكان ما بمهارات نادرة في أماكن أخرى. فضلاً عن ذلك فإن التقدم التكنولوجي السريع في هذا المجال يؤدي أيضاً إلى نقص الخبرة.

على سبيل المثال،

في فبراير 2021، وفقًا للمركز الوطني لبحوث الطب الحيوي، قد تشمل الحواجز الثقافية مقاومة الموظفين لاستخدام العلاج بمساعدة الأدوية (MAT)، ونقص الفعالية الملموسة للعلاج بمساعدة الأدوية، ونقص المعرفة حول كيفية تنفيذ العلاج بمساعدة الأدوية في إطار بيئة العلاج الخاصة بهم. علاوة على ذلك، لا يُعرف سوى القليل عن كيفية ارتباط خصائص المريض بالقرارات التنظيمية المتعلقة بتنفيذ العلاج بمساعدة الأدوية

يوفر تقرير سوق العلاج بمساعدة الأدوية (MAT) تفاصيل عن التطورات الحديثة الجديدة، واللوائح التجارية، وتحليل الاستيراد والتصدير، وتحليل الإنتاج، وتحسين سلسلة القيمة، وحصة السوق، وتأثير اللاعبين المحليين والمحليين في السوق، وتحليل الفرص من حيث جيوب الإيرادات الناشئة، والتغيرات في لوائح السوق، وتحليل نمو السوق الاستراتيجي، وحجم السوق، ونمو سوق الفئات، ومنافذ التطبيق والهيمنة، وموافقات المنتجات، وإطلاق المنتجات، والتوسعات الجغرافية، والابتكارات التكنولوجية في السوق.

تأثير كوفيد-19 على سوق العلاج بمساعدة الأدوية (MAT)

خلال الجائحة، يقلل العلاج بمساعدة الأدوية بشكل ملحوظ من معدل الوفيات والمرض بين مرضى كوفيد-19. هناك حاجة إلى مزيد من الدراسات واسعة النطاق للموافقة على هذه النتائج. يجب تحديد بروتوكول للعلاج بمساعدة الأدوية في عدوى كوفيد-19 لتحقيق أفضل النتائج السريرية الممكنة. أجريت التجارب السريرية خلال كوفيد-19. تعد خدمات علاج اضطراب تعاطي المواد الأفيونية (MOUD) أساسية لمعالجة أزمة المواد الأفيونية، وقد أثر كوفيد-19 بشكل كبير على تقديم خدمات اضطراب تعاطي المواد الأفيونية.

التطورات الأخيرة

في أبريل 2021، أعلنت شركة Adamis Pharmaceuticals Corporation بالتعاون مع USWM عن إطلاق وتوافر منتج ZIMHI عالي الجرعة القابل للحقن من عقار النالوكسون للمساعدة في مكافحة الوفيات الناجمة عن جرعات زائدة من المواد الأفيونية. ومن المتوقع أن يؤدي الإطلاق إلى زيادة إيرادات قطاع المنتجات، مما سيعزز نمو السوق، وتوفير ZIMHI بسعر مخفض للمستجيبين الأوائل ومنظمات الصحة المجتمعية

نطاق سوق العلاج بمساعدة الأدوية العالمية

يتم تقسيم سوق العلاج بمساعدة الأدوية (MAT) على أساس ثمانية قطاعات: النوع، والمنتجات، ونوع الدواء، وشكل الجرعة، وطريقة الإعطاء، ونوع السكان، والمستخدم النهائي وقناة التوزيع. سيساعدك النمو بين هذه القطاعات على تحليل قطاعات النمو الضئيلة في الصناعات وتزويد المستخدمين بنظرة عامة قيمة على السوق ورؤى السوق لمساعدتهم على اتخاذ قرارات استراتيجية لتحديد تطبيقات السوق الأساسية.

يكتب

دواء
مُعَالَجَة

على أساس النوع، يتم تقسيم سوق العلاج بمساعدة الأدوية (MAT) العالمي إلى الأدوية والعلاج.

منتجات

البوبرينورفين والنالوكسون
نالتريكسون
بوبرينورفين
الميثادون
نالوكسون
ديسفلفرام
أكامبروسيت

على أساس المنتجات، يتم تقسيم سوق العلاج بمساعدة الأدوية (MAT) العالمي إلى البوبرينورفين والنالوكسون، النالتريكسون، البوبرينورفين، الميثادون، النالوكسون، الديسلفرام والأكامبروسيت.

نوع الدواء

الأنواع العامة
العلامة التجارية

على أساس نوع الدواء، يتم تقسيم سوق العلاج بمساعدة الأدوية (MAT) العالمي إلى أدوية عامة وأدوية ذات علامات تجارية.

شكل الجرعة

الإفراج الفوري
الإصدار الموسع

على أساس شكل الجرعة، يتم تقسيم سوق العلاج بمساعدة الأدوية (MAT) العالمي إلى إطلاق فوري وإطلاق ممتد.

طريق الإدارة

شفوي
الحقن الوريدي
آحرون

على أساس طريق الإدارة، يتم تقسيم سوق العلاج بمساعدة الأدوية (MAT) العالمي إلى علاج فموي وحقني وغيرها.

نوع السكان

مراهق
البالغون

على أساس نوع السكان، يتم تقسيم سوق العلاج بمساعدة الأدوية (MAT) العالمي إلى البالغين والمراهقين.

المستخدم النهائي

عيادات إعادة التأهيل
المستشفيات
المراكز المتخصصة
الرعاية المنزلية
آحرون

على أساس المستخدم النهائي، يتم تقسيم سوق العلاج بمساعدة الأدوية (MAT) العالمي إلى عيادات إعادة التأهيل والمستشفيات والمراكز المتخصصة والرعاية المنزلية وغيرها.

قناة التوزيع

صيدلية المستشفى
العطاء المباشر
صيدلية التجزئة
صيدلية على الإنترنت
آحرون

سوق العلاج بمساعدة الأدوية

على أساس قناة التوزيع، يتم تقسيم سوق العلاج بمساعدة الأدوية (MAT) العالمي إلى صيدلية المستشفيات، والعطاء المباشر، وصيدلية التجزئة، والصيدلية عبر الإنترنت وغيرها

تحليل/رؤى إقليمية لسوق العلاج بمساعدة الأدوية (MAT)

يتم تحليل سوق العلاج بمساعدة الأدوية (MAT) العالمي، ويتم توفير رؤى حول حجم السوق واتجاهاته حسب المناطق ونوع المنتج والتطبيق وسير العمل والمستخدم النهائي وقناة التوزيع. كما هو مذكور أعلاه.

الدول التي يغطيها تقرير سوق العلاج بمساعدة الأدوية (MAT) هي الولايات المتحدة وكندا والمكسيك وألمانيا وفرنسا والمملكة المتحدة وإيطاليا وإسبانيا وروسيا وتركيا وهولندا وسويسرا والنرويج وبولندا والمجر وليتوانيا والنمسا وأيرلندا وبقية أوروبا والصين واليابان وكوريا الجنوبية والهند وأستراليا وسنغافورة وتايلاند وماليزيا وإندونيسيا والفلبين وفيتنام وبقية دول آسيا والمحيط الهادئ والبرازيل والأرجنتين وبيرو وبقية دول أمريكا الجنوبية وجنوب إفريقيا والمملكة العربية السعودية والإمارات العربية المتحدة ومصر وإسرائيل والكويت وبقية دول الشرق الأوسط وأفريقيا.

ومن المتوقع أن تهيمن أمريكا الشمالية على السوق بسبب ارتفاع حالات اضطرابات تعاطي المخدرات، والتجارب السريرية الجارية، وشركات الأدوية.

سوق العلاج بمساعدة الأدوية

كما يوفر قسم الدولة في التقرير عوامل التأثير الفردية على السوق والتغييرات التنظيمية المحلية التي تؤثر على اتجاهات السوق الحالية والمستقبلية. تعد نقاط البيانات مثل المبيعات الجديدة ومبيعات الاستبدال والتركيبة السكانية للدولة وعلم الأوبئة المرضية ورسوم الاستيراد والتصدير من بين المؤشرات الرئيسية المستخدمة للتنبؤ بسيناريو السوق للدول الفردية. كما يتم النظر في وجود العلامات التجارية العالمية وتوافرها والتحديات التي تواجهها بسبب المنافسة الكبيرة أو النادرة من العلامات التجارية المحلية والمحلية وتأثير قنوات المبيعات أثناء تقديم تحليل تنبؤي لبيانات الدولة.

تحليل المنافسة وحصة سوق العلاج بمساعدة الأدوية (MAT)

يوفر المشهد التنافسي العالمي لسوق العلاج بمساعدة الأدوية (MAT) تفاصيل حسب المنافس. تتضمن التفاصيل نظرة عامة على الشركة، والمالية الخاصة بالشركة، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، والحضور العالمي، ومواقع الإنتاج والمرافق، والقدرات الإنتاجية، ونقاط القوة والضعف في الشركة، وإطلاق المنتج، وعرض المنتج ونطاقه، وهيمنة التطبيق. ترتبط نقاط البيانات المذكورة أعلاه فقط بتركيز الشركات فيما يتعلق بسوق العلاج بمساعدة الأدوية (MAT).

بعض اللاعبين الرئيسيين العاملين في سوق العلاج بمساعدة الأدوية (MAT) هم Indivior PLC وOrexo US Inc. (شركة تابعة لشركة Orexo AB) وRecovery Centers of America وAlkermes. Sun Pharmaceutical Industries Ltd. وPurdue Pharma LP وTaj Pharmaceuticals Limited وLanett وHikma Pharmaceuticals PLC وPfizer Inc. وPinnacle Treatment Center وAmerican Addiction Centers وAdamis Pharmaceuticals Corporation وGlenmark Pharmaceutical Inc. وViatris Inc. وMallinckrodt وAlvogen وAccord Healthcare وVistaPharm, Inc. وTeva Pharmaceutical Industries Ltd. وDr. Reddy's Laboratories Ltd. وAmneal Pharmaceuticals LLC. وTitan Pharmaceuticals, Inc. وغيرها.

SKU-60008

احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم

انقر على الصورة للتكبير

لوحة معلومات تحليل البيانات التفاعلية
لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
تحليل المنافسين باستخدام لوحة معلومات تفاعلية
آخر الأخبار والتحديثات وتحليل الاتجاهات
استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل

طلب التجريبي

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 PRODUCT SEGMENT LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 MARKET END USER COVERAGE GRID

2.11 SECONDARY SOURCES

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 EPIDEMIOLOGY

4.2 PESTEL

4.3 PORTER'S FIVE FORCES MODEL

4.4 ANNUAL INCIDENCE OF SUBJECTS ENTERING MEDICATION-ASSISTED TREATMENT IN ALCOHOL, OPIOID USE DISORDER, AND OPIOID OVERDOSE PREVENTION (2021)

4.5 ANNUAL NUMBER OF TREATMENTS WITH CLONIDINE AND WITH LOFEXIDINE IN OPIOID USE DISORDER AND OPIOID OVERDOSE PREVENTION (2021)

4.6 ANNUAL INCIDENCE OF INDIVIDUALS RE-ENTERING MEDICATION-ASSISTED TREATMENT. FOR EXAMPLE, SOMEONE MAY DROP OUT OF TREATMENT AND RESTART TREATMENT LATER (2021)

4.7 ANNUAL USE OF NALTREXONE INJECTION AS PART OF TREATMENT FOR THE INITIAL WITHDRAWAL FROM OPIOIDS, AND ANNUAL MAINTENANCE THERAPY USING NALTREXONE INJECTION (2021)

4.8 PIPELINE ANALYSIS FOR MEDICATION-ASSISTED TREATMENT (MAT) MARKET

5 GLOBAL MEDICATION-ASSISTED TREATMENT MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 THE RISE IN INCIDENCE OF ALCOHOL USE DISORDER AND OPIOID USE DISORDERS

6.1.2 THE FUNDING BY THE GOVERNMENT FOR MEDICATION-ASSISTED TREATMENT (MAT)

6.1.3 THE RISE IN THE POPULATION RECEIVING MEDICATION-ASSISTED TREATMENT (MAT) AND MEDICATION-ASSISTED AWARENESS PROGRAMMESMEDICATION-ASSISTED TREATMENT (MAT)

6.1.4 USE OF REIMBURSEMENT FOR MEDICATION-ASSISTED TREATMENT (MAT)

6.2 RESTRAINTS

6.2.1 SIDE EFFECTS OF DRUGS USED IN MEDICATION-ASSISTED TREATMENT (MAT)

6.2.2 ETHICAL ISSUES RELATED TO USE OF MEDICATION-ASSISTED TREATMENTMEDICATION-ASSISTED TREATMENT (MAT)

6.2.3 RISE IN PRODUCT RECALLS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS

6.3.2 RISE IN HEALTHCARE EXPENDITURE

6.4 CHALLENGES

6.4.1 THE LACK OF SKILLED PROFESSIONALS, REQUIRED FOR MEDICATION-ASSISTED TREATMENT

6.4.2 STRINGENT REGULATIONS

6.4.3 DISCONTINUATION OF MEDICATION-ASSISTED TREATMENT (MAT)

7 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE

7.1 OVERVIEW

7.2 MEDICATION

7.2.1 OPIOID DEPENDENCY MEDICATION

7.2.1.1 BUPRENORPHINE AND NALOXONE

7.2.1.2 BUPRENORPHINE

7.2.1.3 METHADONE

7.2.1.4 NALTREXONE

7.2.2 ALCOHOL USE DISORDER MEDICATIONS

7.2.2.1 NALTREXONE

7.2.2.2 DISULFIRAM

7.2.2.3 ACAMPROSATE

7.2.3 OPIOID OVERDOSE PREVENTION MEDICATION

7.2.3.1 NALOXONE

7.3 THERAPY

7.3.1 BEHAVIORAL THERAPY

7.3.2 EDUCATIONAL THERAPY

7.3.3 COUNSELLING

7.3.4 VOCATIONAL THERAPY

7.3.5 OTHERS

8 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS

8.1 OVERVIEW

8.2 BUPRENORPHINE AND NALOXONE

8.3 NALTREXONE

8.4 BUPRENORPHINE

8.5 METHADONE

8.6 NALOXONE

8.7 DISULFIRAM

8.8 ACAMPROSATE

9 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE

9.1 OVERVIEW

9.2 GENERICS

9.3 BRANDED

9.3.1 SUBOXONE

9.3.2 VIVITROL

9.3.3 BUTRANS

9.3.4 ZUBSOLV

9.3.5 PROBUPHINE

9.3.6 OTHERS

10 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM

10.1 OVERVIEW

10.2 IMMEDIATE RELEASE

10.3 EXTENDED RELEASE

11 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION

11.1 OVERVIEW

11.2 ORAL

11.2.1 TABLET

11.2.2 SUBLINGUAL FILM

11.2.3 OTHERS

11.3 PARENTERAL

11.3.1 SOLUTION

11.3.2 SUSPENSION

11.4 OTHERS

12 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE

12.1 OVERVIEW

12.2 ADULTS

12.3 TEENAGE

13 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER

13.1 OVERVIEW

13.2 REHABILITATION CLINICS

13.3 HOSPITALS

13.4 SPECIALTY CENTERS

13.5 HOMECARE

13.6 OTHERS

14 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL

14.1 OVERVIEW

14.2 HOSPITAL PHARMACY

14.3 DIRECT TENDER

14.4 RETAIL PHARMACY

14.5 ONLINE PHARMACY

14.6 OTHERS

15 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION

15.1 OVERVIEW

15.2 NORTH AMERICA

15.2.1 U.S.

15.2.2 CANADA

15.2.3 MEXICO

15.3 EUROPE

15.3.1 GERMANY

15.3.2 FRANCE

15.3.3 U.K.

15.3.4 ITALY

15.3.5 RUSSIA

15.3.6 SPAIN

15.3.7 NETHERLANDS

15.3.8 SWITZERLAND

15.3.9 NORWAY

15.3.10 POLAND

15.3.11 HUNGARY

15.3.12 LITHUANIA

15.3.13 AUSTRIA

15.3.14 IRELAND

15.3.15 TURKEY

15.3.16 REST OF EUROPE

15.4 ASIA-PACIFIC

15.4.1 CHINA

15.4.2 JAPAN

15.4.3 INDIA

15.4.4 AUSTRALIA

15.4.5 SOUTH KOREA

15.4.6 SINGAPORE

15.4.7 MALAYSIA

15.4.8 THAILAND

15.4.9 INDONESIA

15.4.10 PHILIPPINES

15.4.11 VIETNAM

15.4.12 REST OF ASIA-PACIFIC

15.5 SOUTH AMERICA

15.5.1 BRAZIL

15.5.2 ARGENTINA

15.5.3 PERU

15.5.4 REST OF SOUTH AMERICA

15.6 MIDDLE EAST AND AFRICA

15.6.1 SOUTH AFRICA

15.6.2 SAUDI ARABIA

15.6.3 U.A.E

15.6.4 ISRAEL

15.6.5 EGYPT

15.6.6 KUWAIT

15.6.7 REST OF MIDDLE EAST AND AFRICA

16 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY LANDSCAPE

16.1 COMPANY SHARE ANALYSIS: GLOBAL

16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

16.3 COMPANY SHARE ANALYSIS: EUROPE

16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17 SWOT ANALYSIS

18 COMPANY PROFILE

18.1 TEVA PHARMACEUTICAL INDUSTRIES LTD. (2021)

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 COMPANY SHARE ANALYSIS

18.1.4 PRODUCT PORTFOLIO

18.1.5 RECENT DEVELOPMENTS

18.2 INDIVOR PLC (2021)

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 COMPANY SHARE ANALYSIS

18.2.4 PRODUCT PORTFOLIO

18.2.5 RECENT DEVELOPMENTS

18.3 VIATRIS INC (2021)

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 COMPANY SHARE ANALYSIS

18.3.4 PRODUCT PORTFOLIO

18.3.5 RECENT DEVELOPMENTS

18.4 SUN PHARMACEUTICAL INDUSTRIES LTD (2021)

18.4.1 COMPANY SNAPSHOT

18.4.2 REVENUE ANALYSIS

18.4.3 COMPANY SHARE ANALYSIS

18.4.4 PRODUCT PORTFOLIO

18.4.5 RECENT DEVELOPMENTS

18.5 ALKERMES (2021)

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 COMPANY SHARE ANALYSIS

18.5.4 PRODUCT PORTFOLIO

18.5.5 RECENT DEVELOPMENTS

18.6 PURDUE PHARMA L.P. (2021)

18.6.1 COMPANY SNAPSHOT

18.6.2 PRODUCT PORTFOLIO

18.6.3 RECENT DEVELOPMENTS

18.7 PFIZER (2021)

18.7.1 COMPANY SNAPSHOT

18.7.2 REVENUE ANALYSIS

18.7.3 PRODUCT PORTFOLIO

18.7.4 RECENT DEVELOPMENTS

18.8 GLENMARK PHARMACEUTICAL INC (2021)

18.8.1 COMPANY SNAPSHOT

18.8.2 REVENUE ANALYSIS

18.8.3 PRODUCT PORTFOLIO

18.8.4 RECENT DEVELOPMENTS

18.9 DR. REDDY’S LABORATORIES LTD (2021)

18.9.1 COMPANY SNAPSHOT

18.9.2 REVENUE ANALYSIS

18.9.3 PRODUCT PORTFOLIO

18.9.4 RECENT DEVELOPMENTS

18.1 ALVOGEN (2021)

18.10.1 COMPANY SNAPSHOT

18.10.2 PRODUCT PORTFOLIO

18.10.3 RECENT DEVELOPMENTS

18.11 ADAMIS PHARMACEUTICALS CORPORATION (2021)

18.11.1 COMPANY SNAPSHOT

18.11.2 REVENUE ANALYSIS

18.11.3 PRODUCT PORTFOLIO

18.11.4 RECENT DEVELOPMENTS

18.12 ACCORD HEALTHCARE (A SUBSIDIARY OF INTAS PHARMACEUTICALS)

18.12.1 COMPANY SNAPSHOT

18.12.2 PRODUCT PORTFOLIO

18.12.3 RECENT DEVELOPMENTS

18.13 AMNEAL PHARMACEUTICALS LLC (2021)

18.13.1 COMPANY SNAPSHOT

18.13.2 REVENUE ANALYSIS

18.13.3 PRODUCT PORTFOLIO

18.13.4 RECENT DEVELOPMENTS

18.14 AMERICAN ADDICTION CENTERS (2021)

18.14.1 COMPANY SNAPSHOT

18.14.2 PRODUCT PORTFOLIO

18.14.3 RECENT DEVELOPMENTS

18.15 HIKMA PHARMACEUTICALS PLC (2021)

18.15.1 COMPANY SNAPSHOT

18.15.2 REVENUE ANALYSIS

18.15.3 PRODUCT PORTFOLIO

18.15.4 RECENT DEVELOPMENTS

18.16 LANNETT (2021)

18.16.1 COMPANY SNAPSHOT

18.16.2 REVENUE ANALYSIS

18.16.3 PRODUCT PORTFOLIO

18.16.4 RECENT DEVELOPMENT

18.17 MALLINCKRODT (2021)

18.17.1 COMPANY SNAPSHOT

18.17.2 REVENUE ANALYSIS

18.17.3 PRODUCT PORTFOLIO

18.17.4 RECENT DEVELOPMENT

18.18 OREXO US INC (A SUBSIDIARY OF OREXO, INC) (2021)

18.18.1 COMPANY SNAPSHOT

18.18.2 REVENUE ANALYSIS

18.18.3 PRODUCT PORTFOLIO

18.18.4 RECENT DEVELOPMENT

18.19 PINNACLE TREATMENT CENTERS

18.19.1 COMPANY SNAPSHOT

18.19.2 PRODUCT PORTFOLIO

18.19.3 RECENT DEVELOPMENT

18.2 RECOVERY CENTERS OF AMERICA

18.20.1 COMPANY SNAPSHOT

18.20.2 PRODUCT PORTFOLIO

18.20.3 RECENT DEVELOPMENTS

18.21 TAJ PHARMACEUTICALS LIMITED

18.21.1 COMPANY SNAPSHOT

18.21.2 PRODUCT PORTFOLIO

18.21.3 RECENT DEVELOPMENTS

18.22 TITAN PHARMACEUTICALS (2021)

18.22.1 COMPANY SNAPSHOT

18.22.2 REVENUE ANALYSIS

18.22.3 PRODUCT PORTFOLIO

18.22.4 RECENT DEVELOPMENTS

18.23 VISTAPHARM, INC (A SUBSIDIARY OF VERTICE PHARMA, LLC. (2021))

18.23.1 COMPANY SNAPSHOT

18.23.2 PRODUCT PORTFOLIO

18.23.3 RECENT DEVELOPMENTS

19 QUESTIONNAIRE

20 RELATED REPORTS

List of Table

TABLE 1 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 2 GLOBAL MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 GLOBAL MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 4 GLOBAL OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 5 GLOBAL ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 6 GLOBAL OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 7 GLOBAL THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 GLOBAL THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 9 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 10 GLOBAL BUPRENORPHINE AND NALOXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 GLOBAL NALTREXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 GLOBAL BUPRENORPHINE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 GLOBAL METHADONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 GLOBAL NALOXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 GLOBAL DISULFIRAM IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 GLOBAL ACAMPROSATE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 18 GLOBAL GENERICS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 GLOBAL BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 GLOBAL BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 21 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 22 GLOBAL IMMEDIATE RELEASE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 GLOBAL EXTENDED RELEASE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 25 GLOBAL ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 GLOBAL ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 27 GLOBAL PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 GLOBAL PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 29 GLOBAL OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 31 GLOBAL ADULTS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 GLOBAL TEENAGE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 34 GLOBAL REHABILITATION CLINICS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 GLOBAL HOSPITALS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 GLOBAL SPECIALTY CENTERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 37 GLOBAL HOMECARE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 38 GLOBAL OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 40 GLOBAL HOSPITAL PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 GLOBAL DIRECT TENDER IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 42 GLOBAL RETAIL PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 43 GLOBAL ONLINE PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 44 GLOBAL OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 45 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 46 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 47 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 48 NORTH AMERICA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 NORTH AMERICA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 NORTH AMERICA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 NORTH AMERICA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 52 NORTH AMERICA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 53 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 54 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 55 NORTH AMERICA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 56 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 57 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 58 NORTH AMERICA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 59 NORTH AMERICA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 60 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 61 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 62 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 63 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 64 U.S. MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 65 U.S. OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 66 U.S. ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 67 U.S. OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 68 U.S. THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 69 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 70 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 71 U.S. BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 72 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 73 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 74 U.S. ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 75 U.S. PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 76 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 77 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 78 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 79 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 CANADA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 81 CANADA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 82 CANADA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 83 CANADA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 84 CANADA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 85 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 86 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 87 CANADA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 88 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 89 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 90 CANADA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 91 CANADA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 92 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 93 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 94 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 95 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 96 MEXICO MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 97 MEXICO OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 98 MEXICO ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 99 MEXICO OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 100 MEXICO THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 101 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 102 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 103 MEXICO BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 104 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 105 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 106 MEXICO ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 107 MEXICO PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 108 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 109 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 110 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 111 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 112 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 113 EUROPE MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 114 EUROPE OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 115 EUROPE ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 116 EUROPE OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 117 EUROPE THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 118 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 119 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 120 EUROPE BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 121 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 122 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 123 EUROPE ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 124 EUROPE PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 125 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 126 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 127 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 128 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 129 GERMANY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 130 GERMANY OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 131 GERMANY ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 132 GERMANY OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 133 GERMANY THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 134 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 135 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 136 GERMANY BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 137 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 138 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 139 GERMANY ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 140 GERMANY PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 141 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 142 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 143 GERMANY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 144 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 145 FRANCE MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 146 FRANCE OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 147 FRANCE ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 148 FRANCE OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 149 FRANCE THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 150 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 151 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 152 FRANCE BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 153 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 154 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 155 FRANCE ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 156 FRANCE PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 157 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 158 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 159 FRANCE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 160 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 161 U.K. MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 162 U.K. OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 163 U.K. ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 164 U.K. OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 165 U.K. THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 166 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 167 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 168 U.K. BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 169 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 170 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 171 U.K. ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 172 U.K. PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 173 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 174 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 175 U.K. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 176 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 177 ITALY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 178 ITALY OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 179 ITALY ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 180 ITALY OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 181 ITALY THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 182 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 183 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 184 ITALY BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 185 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 186 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 187 ITALY ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 188 ITALY PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 189 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 190 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 191 ITALY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 192 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 193 RUSSIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 194 RUSSIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 195 RUSSIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 196 RUSSIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 197 RUSSIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 198 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 199 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 200 RUSSIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 201 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 202 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 203 RUSSIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 204 RUSSIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 205 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 206 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 207 RUSSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 208 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 209 SPAIN MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 210 SPAIN OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 211 SPAIN ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 212 SPAIN OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 213 SPAIN THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 214 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 215 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 216 SPAIN BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 217 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 218 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 219 SPAIN ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 220 SPAIN PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 221 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 222 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 223 SPAIN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 224 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 225 NETHERLANDS MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 226 NETHERLANDS OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 227 NETHERLANDS ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 228 NETHERLANDS OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 229 NETHERLANDS THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 230 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 231 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 232 NETHERLANDS BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 233 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 234 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 235 NETHERLANDS ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 236 NETHERLANDS PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 237 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 238 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 239 NETHERLANDS MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 240 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 241 SWITZERLAND MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 242 SWITZERLAND OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 243 SWITZERLAND ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 244 SWITZERLAND OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 245 SWITZERLAND THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 246 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 247 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 248 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 249 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 250 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 251 SWITZERLAND ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 252 SWITZERLAND PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 253 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 254 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 255 SWITZERLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 256 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 257 NORWAY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 258 NORWAY OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 259 NORWAY ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 260 NORWAY OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 261 NORWAY THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 262 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 263 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 264 NORWAY BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 265 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 266 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 267 NORWAY ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 268 NORWAY PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 269 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 270 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 271 NORWAY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 272 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 273 POLAND MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 274 POLAND OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 275 POLAND ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 276 POLAND OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 277 POLAND THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 278 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 279 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 280 POLAND BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 281 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 282 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 283 POLAND ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 284 POLAND PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 285 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 286 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 287 POLAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 288 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 289 HUNGARY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 290 HUNGARY OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 291 HUNGARY ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 292 HUNGARY OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 293 HUNGARY THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 294 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 295 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 296 HUNGARY BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 297 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 298 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 299 HUNGARY ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 300 HUNGARY PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 301 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 302 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 303 HUNGARY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 304 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 305 LITHUANIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 306 LITHUANIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 307 LITHUANIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 308 LITHUANIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 309 LITHUANIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 310 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 311 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 312 LITHUANIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 313 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 314 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 315 LITHUANIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 316 LITHUANIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 317 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 318 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 319 LITHUANIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 320 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 321 AUSTRIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 322 AUSTRIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 323 AUSTRIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 324 AUSTRIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 325 AUSTRIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 326 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 327 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 328 AUSTRIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 329 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 330 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 331 AUSTRIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 332 AUSTRIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 333 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 334 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 335 AUSTRIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 336 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 337 IRELAND MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 338 IRELAND OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 339 IRELAND ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 340 IRELAND OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 341 IRELAND THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 342 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 343 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 344 IRELAND BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 345 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 346 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 347 IRELAND ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 348 IRELAND PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 349 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 350 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 351 IRELAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 352 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 353 TURKEY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 354 TURKEY OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 355 TURKEY ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 356 TURKEY OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 357 TURKEY THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 358 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 359 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 360 TURKEY BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 361 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 362 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 363 TURKEY ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 364 TURKEY PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 365 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 366 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 367 TURKEY MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 368 REST OF EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 369 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 370 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 371 ASIA-PACIFIC MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 372 ASIA-PACIFIC OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 373 ASIA-PACIFIC ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 374 ASIA-PACIFIC OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 375 ASIA-PACIFIC THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 376 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 377 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 378 ASIA-PACIFIC BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 379 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 380 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 381 ASIA-PACIFIC ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 382 ASIA-PACIFIC PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 383 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 384 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 385 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 386 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 387 CHINA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 388 CHINA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 389 CHINA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 390 CHINA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 391 CHINA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 392 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 393 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 394 CHINA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 395 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 396 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 397 CHINA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 398 CHINA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 399 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 400 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 401 CHINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 402 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 403 JAPAN MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 404 JAPAN OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 405 JAPAN ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 406 JAPAN OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 407 JAPAN THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 408 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 409 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 410 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 411 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 412 JAPAN ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 413 JAPAN PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 414 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 415 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 416 JAPAN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 417 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 418 INDIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 419 INDIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 420 INDIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 421 INDIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 422 INDIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 423 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 424 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 425 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 426 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 427 INDIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 428 INDIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 429 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 430 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 431 INDIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 432 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 433 AUSTRALIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 434 AUSTRALIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 435 AUSTRALIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 436 AUSTRALIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 437 AUSTRALIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 438 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 439 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 440 AUSTRALIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 441 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 442 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 443 AUSTRALIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 444 AUSTRALIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 445 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 446 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 447 AUSTRALIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 448 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 449 SOUTH KOREA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 450 SOUTH KOREA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 451 SOUTH KOREA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 452 SOUTH KOREA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 453 SOUTH KOREA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 454 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 455 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 456 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 457 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 458 SOUTH KOREA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 459 SOUTH KOREA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 460 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 461 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 462 SOUTH KOREA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 463 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 464 SINGAPORE MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 465 SINGAPORE OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 466 SINGAPORE ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 467 SINGAPORE OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 468 SINGAPORE THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 469 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 470 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 471 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 472 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 473 SINGAPORE ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 474 SINGAPORE PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 475 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 476 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 477 SINGAPORE MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 478 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 479 MALAYSIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 480 MALAYSIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 481 MALAYSIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 482 MALAYSIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 483 MALAYSIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 484 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 485 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 486 MALAYSIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 487 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 488 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 489 MALAYSIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 490 MALAYSIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 491 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 492 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 493 MALAYSIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 494 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 495 THAILAND MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 496 THAILAND OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 497 THAILAND ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 498 THAILAND OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 499 THAILAND THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 500 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 501 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 502 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 503 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 504 THAILAND ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 505 THAILAND PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 506 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 507 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 508 THAILAND MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 509 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 510 INDONESIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 511 INDONESIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 512 INDONESIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 513 INDONESIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 514 INDONESIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 515 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 516 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 517 INDONESIA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 518 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 519 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 520 INDONESIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 521 INDONESIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 522 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 523 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 524 INDONESIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 525 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 526 PHILIPPINES MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 527 PHILIPPINES OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 528 PHILIPPINES ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 529 PHILIPPINES OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 530 PHILIPPINES THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 531 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 532 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 533 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 534 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 535 PHILIPPINES ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 536 PHILIPPINES PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 537 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 538 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 539 PHILIPPINES MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 540 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 541 VIETNAM MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 542 VIETNAM OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 543 VIETNAM ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 544 VIETNAM OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 545 VIETNAM THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 546 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 547 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 548 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 549 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 550 VIETNAM ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 551 VIETNAM PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 552 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 553 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 554 VIETNAM MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 555 REST OF ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 556 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 557 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 558 SOUTH AMERICA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 559 SOUTH AMERICA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 560 SOUTH AMERICA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 561 SOUTH AMERICA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 562 SOUTH AMERICA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 563 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 564 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 565 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 566 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 567 SOUTH AMERICA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 568 SOUTH AMERICA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 569 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 570 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 571 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 572 BRAZIL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 573 BRAZIL MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 574 BRAZIL OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 575 BRAZIL ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 576 BRAZIL OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 577 BRAZIL THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 578 BRAZIL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 579 BRAZIL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 580 BRAZIL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 581 BRAZIL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 582 BRAZIL ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 583 BRAZIL PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 584 BRAZIL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 585 BRAZIL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 586 BRAZIL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 587 ARGENTINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 588 ARGENTINA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 589 ARGENTINA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 590 ARGENTINA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 591 ARGENTINA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 592 ARGENTINA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 593 ARGENTINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 594 ARGENTINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 595 ARGENTINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 596 ARGENTINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 597 ARGENTINA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 598 ARGENTINA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 599 ARGENTINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 600 ARGENTINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 601 ARGENTINA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 602 PERU MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 603 PERU MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 604 PERU OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 605 PERU ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 606 PERU OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 607 PERU THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 608 PERU MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 609 PERU MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 610 PERU MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 611 PERU MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 612 PERU ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 613 PERU PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 614 PERU MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 615 PERU MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 616 PERU MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 617 REST OF SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 618 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 619 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 620 MIDDLE EAST AND AFRICA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 621 MIDDLE EAST AND AFRICA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 622 MIDDLE EAST AND AFRICA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 623 MIDDLE EAST AND AFRICA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 624 MIDDLE EAST AND AFRICA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 625 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 626 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 627 MIDDLE EAST AND AFRICA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 628 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 629 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 630 MIDDLE EAST AND AFRICA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 631 MIDDLE EAST AND AFRICA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 632 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 633 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 634 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 635 SOUTH AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 636 SOUTH AFRICA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 637 SOUTH AFRICA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 638 SOUTH AFRICA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 639 SOUTH AFRICA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 640 SOUTH AFRICA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 641 SOUTH AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 642 SOUTH AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 643 SOUTH AFRICA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 644 SOUTH AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 645 SOUTH AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 646 SOUTH AFRICA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 647 SOUTH AFRICA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 648 SOUTH AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 649 SOUTH AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 650 SOUTH AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 651 SAUDI ARABIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 652 SAUDI ARABIA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 653 SAUDI ARABIA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 654 SAUDI ARABIA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 655 SAUDI ARABIA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 656 SAUDI ARABIA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 657 SAUDI ARABIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 658 SAUDI ARABIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 659 SAUDI ARABIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 660 SAUDI ARABIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 661 SAUDI ARABIA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 662 SAUDI ARABIA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 663 SAUDI ARABIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 664 SAUDI ARABIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 665 SAUDI ARABIA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 666 U.A.E MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 667 U.A.E MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 668 U.A.E OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 669 U.A.E ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 670 U.A.E OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 671 U.A.E THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 672 U.A.E MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 673 U.A.E MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 674 U.A.E MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 675 U.A.E MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 676 U.A.E ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 677 U.A.E PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 678 U.A.E MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 679 U.A.E MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 680 U.A.E MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 681 ISRAEL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 682 ISRAEL MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 683 ISRAEL OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 684 ISRAEL ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 685 ISRAEL OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 686 ISRAEL THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 687 ISRAEL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 688 ISRAEL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 689 ISRAEL BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 690 ISRAEL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 691 ISRAEL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 692 ISRAEL ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 693 ISRAEL PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 694 ISRAEL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 695 ISRAEL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 696 ISRAEL MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 697 EGYPT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 698 EGYPT MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 699 EGYPT OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 700 EGYPT ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 701 EGYPT OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 702 EGYPT THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 703 EGYPT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 704 EGYPT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 705 EGYPT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 706 EGYPT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 707 EGYPT ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 708 EGYPT PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 709 EGYPT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 710 EGYPT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 711 EGYPT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 712 KUWAIT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 713 KUWAIT MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 714 KUWAIT OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 715 KUWAIT ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 716 KUWAIT OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 717 KUWAIT THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 718 KUWAIT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 719 KUWAIT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 720 KUWAIT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 721 KUWAIT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 722 KUWAIT ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 723 KUWAIT PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 724 KUWAIT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 725 KUWAIT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 726 KUWAIT MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 727 REST OF MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

List of Figure

FIGURE 1 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET : SEGMENTATION

FIGURE 2 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DBMR POSITION GRID

FIGURE 8 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: END USER COVERAGE GRID

FIGURE 10 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INCREASED INCIDENCE OF ALCOHOL USE DISORDERS AND RISE IN PRODUCT APPROVALS IS EXPECTED TO DRIVE GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET FROM 2022 TO 2029

FIGURE 13 TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET FROM 2022 & 2029

FIGURE 14 NORTH AMERICA IS THE FASTEST GROWING MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR FOR MEDICATION-ASSISTED TREATMENT (MAT) MANUFACTURERS IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET

FIGURE 16 INCIDENCE OF ALCOHOL CONSUMPTION IN 2019

FIGURE 17 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, 2021

FIGURE 18 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 19 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 20 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, LIFELINE CURVE

FIGURE 21 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, 2021

FIGURE 22 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, 2022-2029 (USD MILLION)

FIGURE 23 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, CAGR (2022-2029)

FIGURE 24 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, LIFELINE CURVE

FIGURE 25 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, 2021

FIGURE 26 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION)

FIGURE 27 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, CAGR (2022-2029)

FIGURE 28 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 29 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, 2021

FIGURE 30 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, 2022-2029 (USD MILLION)

FIGURE 31 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, CAGR (2022-2029)

FIGURE 32 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 33 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 34 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)

FIGURE 35 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 36 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 37 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, 2021

FIGURE 38 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, 2022-2029 (USD MILLION)

FIGURE 39 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, CAGR (2022-2029)

FIGURE 40 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 41 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, 2021

FIGURE 42 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 43 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, CAGR (2022-2029)

FIGURE 44 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, LIFELINE CURVE

FIGURE 45 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 46 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 47 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 48 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 49 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SNAPSHOT (2021)

FIGURE 50 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY REGION (2021)

FIGURE 51 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY REGION (2022 & 2029)

FIGURE 52 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY REGION (2021 & 2029)

FIGURE 53 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE (2022-2029)

FIGURE 54 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SNAPSHOT (2021)

FIGURE 55 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021)

FIGURE 56 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2022 & 2029)

FIGURE 57 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021 & 2029)

FIGURE 58 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE (2022-2029)

FIGURE 59 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SNAPSHOT (2021)

FIGURE 60 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021)

FIGURE 61 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2022 & 2029)

FIGURE 62 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021 & 2029)

FIGURE 63 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE (2022-2029)

FIGURE 64 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SNAPSHOT (2021)

FIGURE 65 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021)

FIGURE 66 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2022 & 2029)

FIGURE 67 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021 & 2029)

FIGURE 68 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE (2022-2029)

FIGURE 69 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SNAPSHOT (2021)

FIGURE 70 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021)

FIGURE 71 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2022 & 2029)

FIGURE 72 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021 & 2029)

FIGURE 73 SOUTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE (2022-2029)

FIGURE 74 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SNAPSHOT (2021)

FIGURE 75 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021)

FIGURE 76 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2022 & 2029)

FIGURE 77 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021 & 2029)

FIGURE 78 MIDDLE EAST AND AFRICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE (2022-2029)

FIGURE 79 GLOBAL MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY SHARE 2021 (%)

FIGURE 80 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY SHARE 2021 (%)

FIGURE 81 EUROPE MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY SHARE 2021 (%)

FIGURE 82 ASIA-PACIFIC MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY SHARE 2021 (%)

View Detailed Information

منهجية البحث

يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.

منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.

التخصيص متاح

تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.

Frequently Asked Questions

What are the primary segments covered in the Global Medication Assisted Treatment Mat Market report?

The market is segmented based on Global Medication-Assisted Treatment (MAT) Market, By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and Extended Release), Route of Administration (Oral, Parenteral and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals Specialty Centres, Homecare and Others), Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy and Others), Industry Trends and Forecast to 2029 .

What is the current market size of the Global Medication Assisted Treatment Mat Market?

The Global Medication Assisted Treatment Mat Market size was valued at USD 8191.94 USD Million in 2021.

What is the expected growth rate of the Global Medication Assisted Treatment Mat Market?

The Global Medication Assisted Treatment Mat Market is projected to grow at a CAGR of 9% during the forecast period of 2022 to 2029.

Who are the key players in the Global Medication Assisted Treatment Mat Market?

The major players operating in the market include Indivior PLC, Orexo US , Recovery Centers of America, Alkermes, Sun Pharmaceutical Industries , Purdue Pharma L.P., Taj Pharmaceuticals Limited, Lannett, Hikma Pharmaceuticals PLC, Pfizer , Pinnacle Treatment Center, American Addiction Centers, Adamis Pharmaceuticals Corporation, Glenmark Pharmaceutical , Viatris , Mallkrodt, Alvogen, Accord Healthcare, VistaPharm, Teva Pharmaceutical Industries , Dr. Reddy's Laboratories , Amneal Pharmaceuticals LLC., Titan Pharmaceuticals, .

Which countries are analyzed in the Global Medication Assisted Treatment Mat Market report?

The market report covers data from the By Country (U.S., Canada and Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Norway, Poland, Hungary, Lithuania, Austria, Ireland and Rest of Europe, China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific, Brazil, Argentina, Peru and Rest of South America. South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait and Rest of Middle East and Africa).

السوق العالمية للعلاج بمساعدة الأدوية (MAT) – اتجاهات الصناعة والتوقعات حتى عام 2029

السوق العالمية للعلاج بمساعدة الأدوية (MAT) – اتجاهات الصناعة والتوقعات حتى عام 2029

Global Medication Assisted Treatment Mat Market

CAGR : 9.00 %

ديناميكيات سوق العلاج بمساعدة الأدوية العالمية

تأثير كوفيد-19 على سوق العلاج بمساعدة الأدوية (MAT)

نطاق سوق العلاج بمساعدة الأدوية العالمية

تحليل/رؤى إقليمية لسوق العلاج بمساعدة الأدوية (MAT)

تحليل المنافسة وحصة سوق العلاج بمساعدة الأدوية (MAT)

احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم

Table of Content

List of Table

List of Figure

منهجية البحث

التخصيص متاح

Frequently Asked Questions

التقارير

رؤى السوق

يدعم

حلول

السوق العالمية للعلاج بمساعدة الأدوية (MAT) – اتجاهات الصناعة والتوقعات حتى عام 2029

السوق العالمية للعلاج بمساعدة الأدوية (MAT) – اتجاهات الصناعة والتوقعات حتى عام 2029

Global Medication Assisted Treatment Mat Market

CAGR : 9.00 %

ديناميكيات سوق العلاج بمساعدة الأدوية العالمية

تأثير كوفيد-19 على سوق العلاج بمساعدة الأدوية (MAT)

نطاق سوق العلاج بمساعدة الأدوية العالمية

تحليل/رؤى إقليمية لسوق العلاج بمساعدة الأدوية (MAT)

تحليل المنافسة وحصة سوق العلاج بمساعدة الأدوية (MAT)

احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم

Table of Content

List of Table

List of Figure

منهجية البحث

التخصيص متاح

Frequently Asked Questions

تصفح الصفحات ذات الصلة